726 related articles for article (PubMed ID: 15037526)
1. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
[TBL] [Abstract][Full Text] [Related]
2. Human pharmacology of naproxen sodium.
Capone ML; Tacconelli S; Sciulli MG; Anzellotti P; Di Francesco L; Merciaro G; Di Gregorio P; Patrignani P
J Pharmacol Exp Ther; 2007 Aug; 322(2):453-60. PubMed ID: 17473175
[TBL] [Abstract][Full Text] [Related]
3. Effects of cyclooxygenases inhibitors on vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men.
Tuleja E; Mejza F; Cmiel A; Szczeklik A
Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):1111-5. PubMed ID: 12730088
[TBL] [Abstract][Full Text] [Related]
4. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects.
Capone ML; Sciulli MG; Tacconelli S; Grana M; Ricciotti E; Renda G; Di Gregorio P; Merciaro G; Patrignani P
J Am Coll Cardiol; 2005 Apr; 45(8):1295-301. PubMed ID: 15837265
[TBL] [Abstract][Full Text] [Related]
6. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.
McAdam BF; Catella-Lawson F; Mardini IA; Kapoor S; Lawson JA; FitzGerald GA
Proc Natl Acad Sci U S A; 1999 Jan; 96(1):272-7. PubMed ID: 9874808
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease.
Sciulli MG; Renda G; Capone ML; Tacconelli S; Ricciotti E; Manarini S; Evangelista V; Rebuzzi A; Patrignani P
Clin Pharmacol Ther; 2006 Aug; 80(2):115-25. PubMed ID: 16890573
[TBL] [Abstract][Full Text] [Related]
8. Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings.
Panara MR; Padovano R; Sciulli MG; Santini G; Renda G; Rotondo MT; Pace A; Patrono C; Patrignani P
Clin Pharmacol Ther; 1998 Jun; 63(6):672-81. PubMed ID: 9663182
[TBL] [Abstract][Full Text] [Related]
9. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects.
Panara MR; Renda G; Sciulli MG; Santini G; Di Giamberardino M; Rotondo MT; Tacconelli S; Seta F; Patrono C; Patrignani P
J Pharmacol Exp Ther; 1999 Jul; 290(1):276-80. PubMed ID: 10381787
[TBL] [Abstract][Full Text] [Related]
10. COX-2 is not involved in thromboxane biosynthesis by activated human platelets.
Patrignani P; Sciulli MG; Manarini S; Santini G; Cerletti C; Evangelista V
J Physiol Pharmacol; 1999 Dec; 50(4):661-7. PubMed ID: 10639016
[TBL] [Abstract][Full Text] [Related]
11. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Weir MR; Sperling RS; Reicin A; Gertz BJ
Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
[TBL] [Abstract][Full Text] [Related]
12. Differential inhibition by aspirin of platelet thromboxane and renal prostaglandins in the rat.
Livio M; Benigni A; Zoja C; Begnis R; Morelli C; Rossini M; Garattini S; Remuzzi G
J Pharmacol Exp Ther; 1989 Jan; 248(1):334-41. PubMed ID: 2492341
[TBL] [Abstract][Full Text] [Related]
13. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.
Catella-Lawson F; McAdam B; Morrison BW; Kapoor S; Kujubu D; Antes L; Lasseter KC; Quan H; Gertz BJ; FitzGerald GA
J Pharmacol Exp Ther; 1999 May; 289(2):735-41. PubMed ID: 10215647
[TBL] [Abstract][Full Text] [Related]
14. A prostacyclin-sparing effect of indobufen vs. aspirin.
De Caterina R; Giannessi D; Bernini W; Lazzerini G; Lavezzari M; Stragliotto E; Biagi G; Coccheri S
Thromb Haemost; 1996 Mar; 75(3):510-4. PubMed ID: 8701417
[TBL] [Abstract][Full Text] [Related]
15. Tramadol anti-inflammatory activity is not related to a direct inhibitory action on prostaglandin endoperoxide synthases.
Buccellati C; Sala A; Ballerio R; Bianchib M
Eur J Pain; 2000; 4(4):413-5. PubMed ID: 11124014
[TBL] [Abstract][Full Text] [Related]
16. Reduction of urinary 8-epi-prostaglandin F2 alpha during cyclo-oxygenase inhibition in rats but not in man.
Bachi A; Brambilla R; Fanelli R; Bianchi R; Zuccato E; Chiabrando C
Br J Pharmacol; 1997 Aug; 121(8):1770-4. PubMed ID: 9283716
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of cyclooxygenase-2 enhances platelet adhesion in hamster arterioles in vivo.
Buerkle MA; Lehrer S; Sohn HY; Conzen P; Pohl U; Krötz F
Circulation; 2004 Oct; 110(14):2053-9. PubMed ID: 15451781
[TBL] [Abstract][Full Text] [Related]
18. Selective cyclooxygenase-2 inhibition by nimesulide in man.
Cullen L; Kelly L; Connor SO; Fitzgerald DJ
J Pharmacol Exp Ther; 1998 Nov; 287(2):578-82. PubMed ID: 9808683
[TBL] [Abstract][Full Text] [Related]
19. Urinary excretion of thromboxane and prostacyclin metabolites during chronic low-dose aspirin: evidence for an extrarenal origin of urinary thromboxane B2 and 6-keto-prostaglandin F1 alpha in healthy subjects.
Chiabrando C; Rivoltella L; Martelli L; Valzacchi S; Fanelli R
Biochim Biophys Acta; 1992 Feb; 1133(3):247-54. PubMed ID: 1737057
[TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis.
Belton O; Byrne D; Kearney D; Leahy A; Fitzgerald DJ
Circulation; 2000 Aug; 102(8):840-5. PubMed ID: 10952950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
